Company launched the once-daily formulation ASTAGRAF XL in the U.S. for the indication of prophylaxis of organ rejection in adult patients receiving a kidney transplant. 

In EMEA, despite a continuous increase in sales of the once-daily formulation Advagraf, sales of Prograf (including Advagraf) through Astellas’ own distribution channels declined by 1.3%, to € 530 million on a euro basis, due primarily to price reductions in each country and the impact of generic versions. Sales increased by 23.8%, to ¥71.2 billion when converted to yen due to the impact of foreign exchange rates. Advagraf is sold in 41 countries, and sales of Advagraf accounted for around 35% of combined sales of Advagraf and Prograf in the region. 

In Asia & Oceania, sales grew by 32.1%, to ¥25.0  billion. Sales showed steady growth mainly in China and South Korea. Prograf XL was launched in Indonesia in October 2013. 

## Vesicare (Overactive bladder (OAB) treatment) 

Sales in Japan expanded to ¥30.7 billion, a year-on-year increase of 2.9%. In fiscal 2013, Vesicare’s share in the OAB treatment market was approximately 43% (on a value basis). The combined share of Vesicare and Betanis has reached approximately 60% (on a value basis) and is still expanding. Owing to the considerable number of potential subjects in the OAB treatment market, we will work to increase market penetration of Vesicare and Betanis by raising public awareness of this condition. 

In the Americas, sales of VESIcare rose 2.9%, to US$580 million on a U.S. dollar basis. When converted to yen, sales grew by 24.2%, to ¥58.1 billion. VESIcare’s share in the OAB treatment market reached approximately 22% (on a total prescription basis) in fiscal 2013, maintain- ing the position as the leading branded drug. The com- bined share of VESIcare and Myrbetriq has reached approximately 25% (on a total prescription basis) and is still expanding. 

In EMEA, sales of Vesicare were strong, increasing 13.0%, to € 317 million on a euro basis, while sales grew by 41.7%, to ¥42.7 billion when converted to yen. Vesicare’s share in the OAB treatment market reached approximately 49% (on a value basis) in fiscal 2013. 

In Asia & Oceania, sales of Vesicare increased 29.8%, to ¥3.8 billion. The favorable sales expansion was driven by growth in South Korea. 

## Betanis/Myrbetriq/BETMIGA (generic name: mirabegron, OAB treatment) 

In Japan, sales of Betanis increased to ¥11.6 billion in fiscal 2013, compared with ¥5.3 billion in fiscal 2012. Betanis sales grew steadily in fiscal 2013, having become eligible for long-term prescriptions in October 2012. Betanis’ share of the OAB treatment market reached approximately 16% (on a value basis) in fiscal 2013. 

In the U.S., mirabegron was launched in October 2012 under the brand name Myrbetriq. Myrbetriq sales grew firmly, reaching US$145 million in fiscal 2013, compared with US$20 million in fiscal 2012, on a U.S. dollar basis. When converted to yen, sales were ¥14.5 billion, compared with ¥1.6 billion in fiscal 2012. Myrbetriq’s share of the U.S. OAB treatment market reached approximately 4% (on a total prescription basis) in fiscal 2013. Now that around two years have passed since the launch of Myrbetriq in the U.S., the product has gained a strong reputation from urology specialists in terms of both efficacy and safety. 

In EMEA, mirabegron was launched in the U.K. in Feb- ruary 2013 under the brand name BETMIGA. The distribu- tion of the product has expanded to cover 22 European countries (as of July, 2014), registering € 15 million sales in fiscal 2013 on a euro basis. When converted to yen, sales were ¥2.1 billion. 

In the Asia & Oceania region, this product was launched in Australia in April 2014. 

## Harnal/Omnic (Treatment for functional symptoms associated with benign prostatic hyperplasia (BPH)) 

Sales in Japan declined 11.9% to ¥20.2 billion, due primar- ily to the impact of generic drugs; nevertheless, Harnal still maintained its top position in the alpha-1 blocker market. 

In EMEA, the drug is marketed under the brand name Omnic. In fiscal 2013, sales of Omnic through our own distribution channels rose 0.5%, to € 145 million on a euro basis. When converted to yen, sales rose 26.1%, to ¥19.4 billion. 

